MGMT and colorectal cancer: The evidence supporting the predictive role of gene/protein expression of TYMS–5FU/Capecitabine in colorectal cancers, TUBB3-taxanes in NSCLC and MGMT–temozolomide in brain tumors was modest and mainly from level III observational studies and level IV pre-clinical studies.